Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.56 |
| ▸ | TK2 | O00142 | 3/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.51 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CDA | P32320 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16631591 | 0.82 | PYGM (0.55) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18080033 | 0.82 | P2RY2 (0.63) | DNPH1P2RY2 | |
| SCHEMBL16631533 | 0.81 | LMNA (0.55) | MAPTCDALMNATHRBMTOR | |
| SCHEMBL16631488 | 0.81 | PYGM (0.58) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL16631606 | 0.81 | PYGM (0.53) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL16631649 | 0.81 | PYGM (0.53) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL14853793 | 0.81 | DNPH1 (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL14929135 | 0.81 | DNPH1 (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL14946378 | 0.81 | DNPH1 (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL263751 | 0.81 | DNPH1 (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | PYGM 303/4885TK2 123/4885SLC28A1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.